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SUMMARY. Repaglinide (RGL) loaded polymeric drug delivery devices like microcapsules (MC) and
transdermal patches (TDP) were formulated and there in vitro-in vivo parameters compared to find out
the best route of drug delivery. The formulations were subjected to various studies like hypoglycemic ac-
tivity, glucose tolerance and pharmacokinetic studies. The formulation TDP1 having drug-polymer ratio
1:1 showed comparatively higher RGL release and better permeation across mice skin. Comparatively
higher RGL content was found in TDP1 (99.6 ± 1.8 %) than MC1 (89.2 ± 2.3 %). From the glucose toler-
ance test, transdermal route effectively maintained the normoglycemic levels in contrast to the oral group,
which produced remarkable hypoglycemia. The significantly high area under curve (AUC) values ob-
served with transdermal system also indicate increased bioavailability of drug from these systems com-
pared to oral route. The transdermal system of RGL exhibited better control of hyperglycemia besides
more effectively reversing the complications associated with diabetes mellitus than oral administration in
mice. 
